Sandra Le Quellec

Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab

Yesim Dargaud, Anne Lienhart, Maissaa Janbain et al. · Haematologica · 2018 · 102 citations · Full text

Thrombosis, Venous Thrombosis, Hematology +14

Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome

Matthew C. Sims, Louisa Mayer, Janine Collins et al. · Blood · 2020 · 57 citations · Full text

Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy

Annette von Drygalski, Esteban Moreno Gómez, Adam Giermasz et al. · Blood Advances · 2022 · 56 citations · Full text

Etranacogene Dezaparvovec, Immunodeficiencies, Immunology +19

Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial

Michiel Coppens, Steven W. Pipe, Wolfgang Miesbach et al. · The Lancet Haematology · 2024 · 48 citations · Full text

Translational Medicine, Immunology, Clinical Trials +7

Pre-analytical effects of pneumatic tube system transport on routine haematology and coagulation tests, global coagulation assays and platelet function assays

Sandra Le Quellec, Mickaël Paris, Christophe Nougier et al. · Thrombosis Research · 2016 · 37 citations

Thrombosis, Medicine, Coagulation Tests +11